MAOB and Parkinson disease: MAO-B inhibitors, such as selegiline and rasagiline, have been clinically validated for their efficacy in slowing disease progression and improving symptoms in neurodegenerative conditions, particularly Parkinson’s disease [19], by stabilizing dopamine levels, providing symptomatic relief, and offering potential neuroprotective effects [20].